CN109563169B - 抗hla-g特异性抗体 - Google Patents

抗hla-g特异性抗体 Download PDF

Info

Publication number
CN109563169B
CN109563169B CN201780048691.4A CN201780048691A CN109563169B CN 109563169 B CN109563169 B CN 109563169B CN 201780048691 A CN201780048691 A CN 201780048691A CN 109563169 B CN109563169 B CN 109563169B
Authority
CN
China
Prior art keywords
hla
antibody
ser
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780048691.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563169A (zh
Inventor
P·朗格拉德德穆瓦扬
T·于埃
J·科马丹
M·卢斯托
M·韦贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invectys SAS
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Priority to CN202210678074.5A priority Critical patent/CN115286695A/zh
Publication of CN109563169A publication Critical patent/CN109563169A/zh
Application granted granted Critical
Publication of CN109563169B publication Critical patent/CN109563169B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
CN201780048691.4A 2016-06-03 2017-06-02 抗hla-g特异性抗体 Active CN109563169B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210678074.5A CN115286695A (zh) 2016-06-03 2017-06-02 抗hla-g特异性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305650.0 2016-06-03
EP16305650 2016-06-03
PCT/EP2017/063503 WO2017207775A1 (en) 2016-06-03 2017-06-02 Anti hla-g specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210678074.5A Division CN115286695A (zh) 2016-06-03 2017-06-02 抗hla-g特异性抗体

Publications (2)

Publication Number Publication Date
CN109563169A CN109563169A (zh) 2019-04-02
CN109563169B true CN109563169B (zh) 2022-07-01

Family

ID=56413601

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780048691.4A Active CN109563169B (zh) 2016-06-03 2017-06-02 抗hla-g特异性抗体
CN202210678074.5A Pending CN115286695A (zh) 2016-06-03 2017-06-02 抗hla-g特异性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210678074.5A Pending CN115286695A (zh) 2016-06-03 2017-06-02 抗hla-g特异性抗体

Country Status (14)

Country Link
US (5) US20190233520A1 (cg-RX-API-DMAC10.html)
EP (1) EP3464364A1 (cg-RX-API-DMAC10.html)
JP (2) JP7034950B2 (cg-RX-API-DMAC10.html)
KR (1) KR102465491B1 (cg-RX-API-DMAC10.html)
CN (2) CN109563169B (cg-RX-API-DMAC10.html)
AU (1) AU2017272875B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018074847A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025681A1 (cg-RX-API-DMAC10.html)
EA (1) EA201892793A1 (cg-RX-API-DMAC10.html)
IL (1) IL263266B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018014979A (cg-RX-API-DMAC10.html)
SG (2) SG10202107205VA (cg-RX-API-DMAC10.html)
WO (1) WO2017207775A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201808332B (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
CA3025681A1 (en) 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) * 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
WO2020023268A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
BR112021005868A2 (pt) * 2018-09-27 2021-10-19 Tizona Therapeutics Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
CN118909117A (zh) * 2019-08-14 2024-11-08 安托拉诊疗公司 与lrp6蛋白结合的抗体及使用方法
CN114846156A (zh) * 2019-10-25 2022-08-02 英特莱克森有限责任公司 Hla-h、hla-j、hla-l、hla-v和hla-y作为治疗和诊断靶
CN115996952A (zh) * 2020-06-11 2023-04-21 提圣纳医疗公司 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
CN112794908A (zh) * 2020-12-31 2021-05-14 杭州冰湖生物科技有限公司 一种抗hla-g抗体的制备及分析方法
CN113278590A (zh) * 2021-04-23 2021-08-20 台州恩泽医疗中心(集团) 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
CN114605543B (zh) * 2021-12-17 2023-11-07 台州恩泽医疗中心(集团) 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
AU2023216270A1 (en) 2022-02-04 2024-08-15 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
CN118946585A (zh) * 2022-03-25 2024-11-12 怡诺安有限公司 抗hla-g嵌合抗原受体及其用途
US20250297013A1 (en) * 2022-03-25 2025-09-25 Hk Inno.N Corporation Hla-g-specific antibody and use thereof
CN115894687B (zh) * 2022-03-31 2024-06-07 台州恩泽医疗中心(集团) 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
CN116284387B (zh) * 2022-07-15 2025-10-03 台州恩泽医疗中心(集团) 一种抗hla-g2及hla-g6分子的单克隆抗体及用途
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体，及应用
CN115975033A (zh) * 2022-10-10 2023-04-18 中国科学院微生物研究所 一种lilrb1单克隆抗体及其应用
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119080938B (zh) * 2023-06-05 2025-06-24 东莞市朋志生物科技有限公司 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
EP4793288A1 (en) * 2023-10-12 2026-08-19 Imbiologics Corp. Antibody specifically binding to hla-g, and use thereof
CN121005780A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 靶向hla-g的抗体或其抗原结合片段及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CN1718588A (zh) * 2004-10-26 2006-01-11 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用
WO2008121894A3 (en) * 2007-03-30 2009-04-23 Escape Therapeutics Inc Endogenous expression of hla-g and/or hla-e by mesenchymal cells
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2264067A1 (en) * 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
CN101967191A (zh) * 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
CN102086459A (zh) * 2009-12-08 2011-06-08 华中科技大学 一种融合蛋白免疫抑制剂及其制备方法和应用
WO2014072534A1 (en) * 2012-11-12 2014-05-15 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
CA3025681A1 (en) 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CN1718588A (zh) * 2004-10-26 2006-01-11 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用
WO2008121894A3 (en) * 2007-03-30 2009-04-23 Escape Therapeutics Inc Endogenous expression of hla-g and/or hla-e by mesenchymal cells
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2264067A1 (en) * 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
CN101967191A (zh) * 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
CN102086459A (zh) * 2009-12-08 2011-06-08 华中科技大学 一种融合蛋白免疫抑制剂及其制备方法和应用
WO2014072534A1 (en) * 2012-11-12 2014-05-15 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Crystal structure of HLA-G a nonclassical MHC class I molecule expressed at the fetal-maternal interface;Craig S. Clements等;《PNAS》;20050301;第102卷(第9期);全文，特别是摘要、图2、图5、第3364页右栏第1段 *
Generation of an antibody to HLA-G in transgenic mice and demonstration of the tissue reactivity of this antibody;Gill Chumbley等;《Journal of Reproductive Immunology》;19941231;第27卷(第3期);第173-186页 *
HLA-G expression in human ovarian carcinoma counteracts NK cell function;A.Lin等;《Annals of Oncology》;20071130;第18卷(第11期);第1804-1809页 *
可溶性人白细胞抗原G的研究进展;张天骄等;《国外医学计划生育/生殖健康分册》;20071231;第26卷(第6期);第305-308页 *

Also Published As

Publication number Publication date
NZ788807A (en) 2025-11-28
US20210309748A1 (en) 2021-10-07
EA201892793A1 (ru) 2019-06-28
JP7034950B2 (ja) 2022-03-14
AU2017272875A1 (en) 2018-12-20
IL263266A (en) 2018-12-31
CA3025681A1 (en) 2017-12-07
US11634494B2 (en) 2023-04-25
US11312774B2 (en) 2022-04-26
US20220251216A1 (en) 2022-08-11
WO2017207775A1 (en) 2017-12-07
AU2017272875B2 (en) 2023-10-19
KR102465491B1 (ko) 2022-11-11
IL263266B2 (en) 2024-07-01
US20210054081A1 (en) 2021-02-25
NZ748929A (en) 2025-11-28
SG11201810149VA (en) 2018-12-28
EP3464364A1 (en) 2019-04-10
CN109563169A (zh) 2019-04-02
BR112018074847A2 (pt) 2019-03-26
JP2022084670A (ja) 2022-06-07
SG10202107205VA (en) 2021-08-30
IL263266B1 (en) 2024-03-01
KR20190044589A (ko) 2019-04-30
CN115286695A (zh) 2022-11-04
US11111302B2 (en) 2021-09-07
JP2019528038A (ja) 2019-10-10
US20220056140A1 (en) 2022-02-24
ZA201808332B (en) 2019-08-28
US20190233520A1 (en) 2019-08-01
MX2018014979A (es) 2019-10-14

Similar Documents

Publication Publication Date Title
US11634494B2 (en) Anti HLA-G specific antibodies
JP7215759B2 (ja) ４－１ｂｂ抗体およびその製造方法と使用
KR102372274B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
CN112778418B (zh) 对cd73具有特异性的结合分子及其用途
CN107973854B (zh) Pdl1单克隆抗体及其应用
CN110462038A (zh) 抗gprc5d抗体和包含所述抗体的分子
CN113004408B (zh) 抗人程序死亡因子-1单克隆抗体
CN113194994A (zh) 使用抗trem2抗体的方法
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
KR20210069058A (ko) 항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
CN113039208A (zh) 一种抗pd-l1抗原结合蛋白及其应用
EP4663661A1 (en) Anti-cdh6 antibody and use thereof
CN114008077A (zh) 抗体和使用方法
CN112625130A (zh) 抗-tigit抗体及使用之方法
CN114957468A (zh) 一种抗Siglec15抗体及其用途
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
JP2022505144A (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
CN115521378B (zh) Pd-l1抗体及其用途
EA043548B1 (ru) Анти-hla-g специфические антитела
CN118165107A (zh) 结合tigit的抗体分子
CN118900847A (zh) 结合b7-h3的抗体及其用途
HK40016809B (en) High affinity antibodies to cd39 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant